Vimarsana
Biggest News Aggregation in the World

Ffecting Cognitive Function News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from Ffecting Cognitive Function. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In Ffecting Cognitive Function Today - Breaking & Trending Today

Actinogen presents positive Phase 2a Xanamem data in at ADPD Alzheimer's and Parkinson's diseases conference - Vimarsana News

Actinogen presents positive Phase 2a Xanamem data in at ADPD Alzheimer's and Parkinson's diseases conference

Published: March 30, 2023

A longitudinal dataset indicating the utility of plasma pTau for patient selection in clinical trials of patients with mild Alzheimer's Disease (AD) and the likely therapeutic benefit of oral Xanamem in this population SYDNEY, March 30, 2023 /PRNewswire/ -- Actinogen Medical ASX: ACW ("ACW" or "the Company")is pleased to announce that its Chief Medical Officer, Dr Dana Hilt will make an oral presentation to the International Conference on Alzheimer's and Parkinson's Diseases and related neurological disorders (ADPD2023)later today in Gothenburg, Sweden. Dr Hilt ...

Source: singaporestar.com
Related Topics:
New South WalesVastra Gotalands LanSteven GourlayMichael RobertsAd Drug Development Clinical TrialsInternational Conference On AlzheimerChief Medical OfficerInternational ConferenceDevelopment ClinicalClinical Dementia Rating ScaleNeurologic Test BatteryA Longitudinal Dataset Indicating The Utility Of Plasma Ptau For Patient Selection In Clinical Trials Patients With Mild Alzheimer 39s Disease Ad And Likely Therapeutic Benefit Oral Xanamem This Population SydneyMarch 30023 Prnewswire Actinogen Medical Asx Acw Quot Or The Company Is Pleased To Announce That Its Chief OfficerR Dana Hilt Will Make An Oral Presentation To The International Conference On Alzheimer 39s And Parkinson Diseases Related Neurological Disorders Adpd2023 Later Today In GothenburgWeden Dr Hilt Was Invited To Present Actinogen 39s Novel Phase 2a Data As An Oral Presentation Ina Symposium Session Entitled Ad Drug Development Clinical Trials The Details Unique Longitudinal Dataset Demonstrating 1 Utility Of Using Plasma Biomarker Ptau181 For Selection Patients Witha More Progressive Form Mild In And 2 Encouraging Beneficial Effect Xanamem On Endpoints Function Cdr Sb Cognition Ntb These His Analyses Four Studies That Have Shown Positive Results Acw Small Molecule Pave Way 330 Person Xanamia 2b Trial Commence Coming Months Key Points Include Most Anti Amyloid Therapies Failed Recent Lecanemab Shows Onlya ModestUggesting The Utility Of Quot Amyloid Hypothesis In Ad Is Limited There Isa Strong Scientific Rationale For Targeted Modulation Brain Cortisol Several Diseases Including And Depression Xanamem Penetrant Small Molecule Inhibitor Tissue Synthesis That Does Not Disturb Normal Homeostasis Regulated By Adrenal Gland Production Four Independent Clinical Studies Have Shown Positive Resultsa Human Pet Study Visualized High Levels Target Engagement Thereby Establishing Suitability Low Doses 5 Mg 10 Daily Investigation Two RandomizedLacebo Controlled Trials Showed The Same Pattern Of Improved Attention And Working MemoryOth Key Aspects Of CognitionN OlderOgnitively Normal Volunteers Analysis Of Biomarker Positive Plasma Ptau181 Patients With Mild Ad Ina Phase 2a Trial Showed Clinically Significant Benefits On Function Cdr Sb And Cognition Ntb Excellent Safety Tolerability Profile In More Than 300 People Treated 1 Clinical Dementia Rating Scale Sum Boxes Neurologic Test Battery The Upcoming Xanamia 2b Will Study 330 Individuals 5 Mg0 Mg Or Placebo Over 24 Weeks Patients Will Have Early StageRogressive Ad Defined As Mild Cognitive Impairment Mci Or And Elevated Plasma Ptau181 Key Endpoints Will Bea Composite Based On The Ntb Described In Dr Hilt 39s Presentation Cdr Sb Be Available At Https Actinogen Com Au Corporate Presentations Steven GourlayCtinogen 39s Ceo And MdAid Quot Actinogen Is Excited To Present Its Novel Phase 2a Dataset That One Of The First Show Blood Ptau Biomarker Isa Highly Effective Method For Selection Patients Witha Progressive Form Mild Alzheimer 39s Disease Asa Simulation Upcoming 2b Xanamia Trial Data Give Us Confidence In Our Study Design
Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial - Vimarsana News

Actinogen announces first patient treated in depression and cognitive impairment Phase 2 clinical trial

Published: December 15, 2022

Approximately 5% of Americans suffer from Major Depressive Disorder (MDD),[1]which is commonly associated with "foggy thinking" but a new clinical trial raises hope that once-a-day oral drug Xanamemmay assist where treatment by anti-depressant medication alone is inadequate SYDNEY, Dec. 14, 2022 /PRNewswire/ --Actinogen Medical Limited (ASX: ACW)is pleased to announce that the first patient has been randomized and treated in the XanaCIDD Phase 2 depression clinical trial that will measure the effects of Xanamem on safety, cognitive performance and depression in patients who are inade...

Source: philippinetimes.com
Related Topics:
New South WalesUnited StatesSteven GourlayActinogen Medical LimitedMajor Depressive DisorderCogstate Cognitive Test BatteryMontgomery Asberg Depression Rating ScaleFragilex SyndromeApproximately 5 Of Americans Suffer From Major Depressive Disorder Mdd Dec 14022 Prnewswire Actinogen Medical Limited Asx Acw Is Pleased To Announce That The First Patient Has Been Randomized And Treated In Xanacidd Phase 2 Depression Clinical Trial Will Measure Effects Of Xanamem On SafetyOgnitive Performance And Depression In Patients Who Are Inadequately Treated By Their Anti Depressant Medication Have Both Depressive Symptoms Cognitive Impairment Dr Steven GourlayCtinogen 39s Ceo And MdAid Quot We Are Very Pleased To Announce The Formal Start Of Our Trial In Patients With Mdd And Cognitive Impairment Who Inadequately Treated By Their Current Anti Depressant Medication There Isa Strong Scientific Rationale For Reducing Brain Cortisol Levels Improve Symptoms Depression Xanamem Has Already Been Proven Enhance Cognition Three Independent Clinical Trials Safety Demonstrated More Than 300 Volunteers Date Potential Be An Effective Low Dose Daily Oral Therapy TreatmentLzheimer 39s Disease And Many Other Neurological Conditions Where It May Be Used Alone Or In Combination With Treatments Quot The Xanacidd Phase 2 Depression Trial Isa Six Week Proof Of ConceptPlacebo ControlledArallel Group Design Trial In Approximately 160 Patients With Persistent Mdd And Cognitive Impairment Despitea Standard Course Of Anti Depressant Therapy Xanamem 10 Mg Daily Or Placebo Will Be Added To The Existing Effects On CognitionSing The Cogstate Cognitive Test BatteryEnd DepressionSing The Montgomery Asberg Depression Rating ScaleIll Be Assessed Trial Results Are Expected In Late 2023 Or Early 2024 About Actinogen Medical Acw Is An Asx ListedIotechnology Company Developinga Novel Therapy For Neurological And Neuropsychiatric Diseases Associated With Dysregulated Brain Cortisol There Isa Strong Association Between Detrimental Changes In TheFfecting Cognitive FunctionArm To Brain Cells And Long Term Cognitive Health Function Means Howa Person UnderstandsEmembers And Thinks Clearly Cognitive Functions Include Memory